Eva Gil Berglund

Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

Ping Zhao, L Zhang, Joseph A. Grillo et al. · Clinical Pharmacology & Therapeutics · 2010 · 507 citations

Drug Evaluation, Translational Medicine, Physiologically Based Pharmacokinetics +15

Physiologically based pharmacokinetic modeling in regulatory decision‐making at the European Medicines Agency

Elisa Luzon, Kevin Blake, Susan Cole et al. · Clinical Pharmacology & Therapeutics · 2016 · 129 citations

European Medicines Agency, Physiologically Based Pharmacokinetics, Pharmacokinetic Modeling +14

Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

Md L T Vieira, Brian J. Kirby, Isabelle Ragueneau‐Majlessi et al. · Clinical Pharmacology & Therapeutics · 2013 · 101 citations

Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

Ping Zhao, Manuela de Lima Toccafondo Vieira, Joseph A. Grillo et al. · The Journal of Clinical Pharmacology · 2012 · 96 citations

Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

Joseph A. Grillo, Ping Zhao, Julie Bullock et al. · Biopharmaceutics & Drug Disposition · 2012 · 93 citations